Peak Retirement Planning Inc. Invests $2.84 Million in Hims & Hers Health, Inc. $HIMS

Peak Retirement Planning Inc. acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 50,096 shares of the company’s stock, valued at approximately $2,841,000. Hims & Hers Health comprises about 0.8% of Peak Retirement Planning Inc.’s portfolio, making the stock its 22nd largest position.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Quent Capital LLC purchased a new stake in Hims & Hers Health in the 3rd quarter valued at $28,000. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter valued at approximately $26,000. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health in the second quarter worth approximately $29,000. Bessemer Group Inc. increased its stake in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the last quarter. Finally, Hilltop National Bank purchased a new stake in Hims & Hers Health in the third quarter valued at $35,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 2.4%

Shares of HIMS opened at $26.45 on Tuesday. The company’s 50-day simple moving average is $34.11 and its 200-day simple moving average is $44.09. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The stock has a market capitalization of $6.02 billion, a PE ratio of 48.97, a P/E/G ratio of 4.46 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the previous year, the company earned $0.32 earnings per share. Hims & Hers Health’s quarterly revenue was up 49.2% on a year-over-year basis. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has initiated a stock buyback program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HIMS. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. BTIG Research decreased their target price on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. Finally, Zacks Research lowered shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $42.62.

Insiders Place Their Bets

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the transaction, the insider owned 6,175 shares of the company’s stock, valued at $226,684.25. This represents a 53.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 131,974 shares of company stock valued at $4,763,800. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.